When the National Psoriasis Foundation was founded in 1967, individuals living with chronic conditions including psoriasis and psoriatic arthritis had few options to effectively manage their disease. Fortunately, over the last few decades, scientific advancements have led to the development of many life saving and life altering therapies. The psoriatic disease community is one community that has benefited from this progress. Today, individuals with psoriasis and psoriatic arthritis at all levels of disease severity have numerous safe and effective choices to manage their disease.
NPF Leads in Bringing the Patient Voice into Discussions of Value
NPF is one of a handful of patient organizations leading the cry that any efforts which calculate value must consider what is truly meaningful to individuals living with these diseases. Patient insights, preferences, and priorities must be more than background contextual considerations. They must be data inputs in value calculations. Just as we have made significant improvement in engaging patients in drug development, we must also engage the patient community in this work. Only then will value assessment lead to improved patient health outcomes. In the last several years, NPF has been at the forefront of bringing this message to value modelers by participating in two Institute for Clinical and Economic Review (ICER) value assessments for psoriasis therapies (in 2016 and 2018), to health insurers and pharmacy benefit managers via five years of payer roundtables and numerous individual dialogues, and to academics and others engaged in expanding the role of value assessment through collaborations, partnerships, and summit dialogues.